Reach Neuro

Reach Neuro operates in neurotechnology and medical devices, pursuing an implantable spinal cord stimulation approach for chronic stroke-related movement impairment. Its stated focus is upper-limb recovery—particularly shoulder, arm, and hand movement—using stimulation targeted to the cervical spinal cord and individualized programming. This specialization distinguishes the company’s stated product direction from a general rehabilitation offering, while its implantable system and personalized protocols make it a device-based intervention rather than a stand-alone digital therapy. The company received FDA Breakthrough Device designation for its motor-function-restoration platform in 2023, a meaningful regulatory milestone, though it does not by itself establish approval, effectiveness, or commercial availability. The available comparable-company entries repeat Reach Neuro itself rather than identifying independent peers, so there is no reliable basis here to name or rank direct competitors. Its market position is therefore best understood by its clinical target and technical approach, not by unsupported competitor comparisons. With a 1–10 employee range and two recorded financing rounds, it remains an early-stage company in a research- and regulatory-intensive field.

Reach Neuro’s trajectory shows a transition from early formation and financing toward continued development of its spinal cord stimulation platform. Its pre-seed round is dated Jan 1, 2022, with SOSV SF & NY (formerly IndieBio) identified as an investor; the amount is undisclosed. In 2023, the company received FDA Breakthrough Device designation for its motor-function-restoration platform, marking a regulatory inflection point. A Mar 20, 2024 report described further refinement of its neurostimulation method for motor disorders. The next recorded financing milestone was a seed round on May 28, 2025, led by Angel Investor Forum, again with no public amount specified. The company is listed in the 1–10 employee range, but no hiring trend, workforce growth, or layoff activity is reported.